Clover Health Investments vs Molina Healthcare
CLOV and MOH side by side, both in accident and health insurance and medical. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLOV and MOH compare
Molina Healthcare is the larger company, worth 4.1 times as much as Clover Health Investments ($10.9B against $2.6B).
Clover Health Investments grew revenue faster over the last twelve months (54.5% versus −0.95% for Molina Healthcare).
Clover Health Investments keeps more of each dollar of sales as profit, with a net margin of 0.45% compared with −0.11% at Molina Healthcare.
Clover Health Investments scores higher on the StockData Score (6 against 5 for Molina Healthcare), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLOV | MOH |
|---|---|---|
| Size and price | ||
| Market cap | $2.6B | $10.9B |
| Share price | $4.97 | $209.25 |
| Change, 1 year | 91.2% | 48.5% |
| Change, 5 years | −13.6% | −29.8% |
| Beta (5Y) | 1.66 | 0.25 |
| Employees | 724 | 19K |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 497× | – |
| P/S | 1.0× | 0.2× (better) |
| P/B | 6.8× | 2.6× (better) |
| EV/EBITDA | 182× | 18.4× (better) |
| P/FCF | 20.0× (better) | 45.9× |
| FCF yield | 5.0% (better) | 2.2% |
| Growth | ||
| Revenue growth (TTM) | 54.5% (better) | −0.95% |
| Revenue growth, 5Y average | 23.4% (better) | 18.5% |
| Net income growth (TTM) | – | −105% |
| EPS growth (TTM) | – | −106% |
| EPS growth, 5Y average | – | −4.5% |
| Profitability | ||
| Gross margin | – | 12.6% |
| Operating margin | 0.45% (better) | 0.39% |
| Net margin | 0.45% (better) | −0.11% |
| FCF margin | 4.8% (better) | 0.54% |
| Return on equity | 3.4% (better) | −1.2% |
| Return on invested capital | 9.6% | – |
| Financial health | ||
| Debt / equity | – | 0.91 |
| Net debt / EBITDA | – | −14.44 |
| Interest coverage | – | 0.8× |
| Current ratio | 1.55 | 1.69 (better) |
| Altman Z-score | 4.22 (better) | 4.15 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 27.5% | 108% |
| Held by insiders | 23.5% | 1.5% |
| Insider net buying, 12 months | −$8.7M | −$3.4M (better) |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 5.7% | 5.7% |
Go deeper
- CLOV stock overview
- CLOV income statement
- CLOV valuation and score
- MOH stock overview
- MOH income statement
- MOH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.